Home  |  Contact

UniProtKB/Swiss-Prot P13569: Variant p.Ser1235Arg

Cystic fibrosis transmembrane conductance regulator
Gene: CFTR
Variant information

Variant position:  1235
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Serine (S) to Arginine (R) at position 1235 (S1235R, p.Ser1235Arg).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from small size and polar (S) to large size and basic (R)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In CF.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  1235
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  1480
The length of the canonical sequence.

Location on the sequence:   LTAKYTEGGNAILENISFSI  S PGQRVGLLGRTGSGKSTLLS
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         LTAKYTEGGNAILENISFSISPGQRVGLLGRTGSGKSTLLS

Gorilla                       LTAKYTEGGNAILENISFSISPGQRVGLLGRTGSGKSTLLS

                              LTAKYIDGGNAILENISFSISPGQRVGLLGRTGSGKSTLLS

Rhesus macaque                LTAKYTEGGNPILENISFSISPGQRVGLLGRTGSGKSTLLS

Chimpanzee                    LTAKYTEGGNAILENISFSISPGQRVGLLGRTGSGKSTLLS

Mouse                         LTVKYMDDGNAVLENISFSISPGQRVGLLGRTGSGKSTLLS

Rat                           LTVKYVDDGNAILENISFSISPGQRVGLLGRTGSGKSTLLS

Pig                           LTAKYVDGGNAVLENISFSISPGQRVGLLGRTGSGKSTLLL

Bovine                        LTAKYTDGGNAILENISFSISPGQRVGLLGRTGSGKSTLLL

Rabbit                        LTAKYIDSGNAILENISFSISPGQRVGLLGRTGSGKSTLLS

Sheep                         LTAKYIDGGNAILENISFSISPGQRVGLLGRTGSGKSTLLL

Horse                         LTAKYTDGGNAILENISFSISPGQRVGLLGRTGSGKSTLLS

Xenopus laevis                LSANYIDGGNTVLENISFSLSPGQRVGLLGRTGSGKSTLLS

Zebrafish                     LTVKYTEAGHAVLKNLSFSAEGRQRVGILGRTGSGKSSLFN

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 1480 Cystic fibrosis transmembrane conductance regulator
Topological domain 1152 – 1480 Cytoplasmic
Domain 1210 – 1443 ABC transporter 2
Binding site 1219 – 1219 ATP 2
Alternative sequence 606 – 1480 Missing. In isoform 3.
Mutagenesis 1250 – 1250 K -> M. No effect on maturation of glycans, suggesting that trafficking to the plasma membrane is not altered.


Literature citations

No reference for the current variant in UniProtKB/Swiss-Prot.

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.